Evidence map›Paper›PMID 32773603›Full record

ReviewPain2020

The role of cyclin-dependent kinase 5 in neuropathic pain.

Kimberly Gomez, Tissiana G M Vallecillo, Aubin Moutal, Samantha Perez-Miller, Rodolfo Delgado-Lezama, Ricardo Felix, Rajesh Khanna

Open access · greenAbstract readReview
In one paragraph

Review in Pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 40 citations in OpenAlex.

  1. The Recycling Endosomal (NaActa physiologica (Oxford, England) · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Biosynthesis inhibition of miR-142-5p in a NCellular & molecular biology letters · 2025
    Article
  6. CDK5: Insights into its roles in diseases.Molecular biology reports · 2025
    Review
  7. Regulatory Action of Calcium and Calcium Channels in Pain Pathways.International journal of biological sciences · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The role of Cdk5 in neurological disorders.Frontiers in cellular neuroscience · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Non-SUMOylated CRMP2 decreases NaMolecular brain · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Kimberly GomezDepartment of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.
Tissiana G M VallecilloDepartment of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.
Aubin MoutalDepartment of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.
Samantha Perez-MillerDepartment of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.
Rodolfo Delgado-LezamaDepartment of Physiology, Biophysics and Neuroscience, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico.
Ricardo FelixDepartment of Cell Biology, Cinvestav, Mexico City, Mexico.
Rajesh KhannaDepartment of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.
University of Arizona · USCenter for Research and Advanced Studies of the National Polytechnic Institute · MXCenter for Innovation · US

Funding

CRMP2, mitochondria, and Huntington’s diseaseR01NS098772 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI BRUSTOVETSKY, NICKOLAY, KHANNA, RAJESH · 2017 to 2021
$2.8M
Sentrin proteases, CRMP2 deSUMOylation, and Chronic PainR01NS120663 · NINDS · UNIVERSITY OF FLORIDA · PI KHANNA, RAJESH · 2020 to 2021
$2.6M
CRMP2, Nav1.7 sodium channel, and chronic painR01DA042852 · NIDA · UNIVERSITY OF ARIZONA · PI KHANNA, RAJESH · 2017 to 2021
$1.9M
Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug CandidatesR41CA210857 · NCI · REGULONIX, LLC · PI KHANNA, RAJESH · 2017 to 2017
$300k
NCI NIH HHS R41 CA210857NIDA NIH HHS R01 DA042852NINDS NIH HHS R01 NS098772NINDS NIH HHS R01 NS120663
6 · The paper itself

Abstract

The chronification of pain can be attributed to changes in membrane receptors and channels underlying neuronal plasticity and signal transduction largely within nociceptive neurons that initiate and maintain pathological pain states. These proteins are subject to dynamic modification by posttranslational modifications, creating a code that controls protein function in time and space. Phosphorylation is an important posttranslational modification that affects ∼30% of proteins in vivo. Increased phosphorylation of various nociceptive ion channels and of their modulators underlies sensitization of different pain states. Cyclin-dependent kinases are proline-directed serine/threonine kinases that impact various biological and cellular systems. Cyclin-dependent kinase 5 (Cdk5), one member of this kinase family, and its activators p35 and p39 are expressed in spinal nerves, dorsal root ganglia, and the dorsal horn of the spinal cord. In neuropathic pain conditions, expression and/or activity of Cdk5 is increased, implicating Cdk5 in nociception. Experimental evidence suggests that Cdk5 is regulated through its own phosphorylation, through increasing p35's interaction with Cdk5, and through cleavage of p35 into p25. This narrative review discusses the molecular mechanisms of Cdk5-mediated regulation of target proteins involved in neuropathic pain. We focus on Cdk5 substrates that have been linked to nociceptive pathways, including channels (eg, transient receptor potential cation channel and voltage-gated calcium channel), proteins involved in neurotransmitter release (eg, synaptophysin and collapsin response mediator protein 2), and receptors (eg, glutamate, purinergic, and opioid). By altering the phosphoregulatory "set point" of proteins involved in pain signaling, Cdk5 thus appears to be an attractive target for treating neuropathic pain conditions.

Indexed as

Cyclin-Dependent Kinase 5NeuralgiaGanglia, SpinalHumansPhosphorylationSignal TransductionCDK5 protein, humanCyclin-Dependent Kinase 5

Identifiers

PMID32773603
PMCPMC7669638
OpenAlexW3047762449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.